Blueprint Medicines Says BLU-222 Combination Well Tolerated for Inhibitor in Type of Breast Cancer
Blueprint Medicines Says BLU-222 Combination Well Tolerated for Inhibitor in Type of Breast Cancer
Blueprint Medicines 表示，在乳腺癌類型中，BLU-222 組合對抑制劑的耐受性良好
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊